期刊
JOURNAL OF MEDICINAL CHEMISTRY
卷 57, 期 15, 页码 6822-6833出版社
AMER CHEMICAL SOC
DOI: 10.1021/jm500871s
关键词
-
资金
- National Institute of General Medical Sciences of the National Institutes of Health [R01GM103893]
- University Cancer Research Fund from University of North Carolina at Chapel Hill
- V Foundation for Cancer Research
- Structural Genomics Consortium from the Canada Foundation for Innovation [1097737]
- Eli Lilly Canada
- GlaxoSmithKline
- Ontario Ministry of Economic Development and Innovation
- Novartis Research Foundation
- Pfizer
- AbbVie
- Takeda
- Janssen
- Boehringer Ingelheim
- Bayer
- Wellcome Trust
The lysine methyltransferase SETD8 is the only known methyltransferase that catalyzes monomethylation of histone H4 lysine 20 (H4K20). Monomethylation of H4K20 has been implicated in regulating diverse biological processes including the DNA damage response. In addition to H4K20, SETD8 monomethylates non-histone substrates including proliferating cell nuclear antigen (PCNA) and promotes carcinogenesis by deregulating PCNA expression. However, selective inhibitors of SETD8 are scarce. The only known selective inhibitor of SETD8 to date is nahuoic acid A, a marine natural product, which is competitive with the cofactor. Here, we report the discovery of the first substrate-competitive inhibitor of SETD8, UNC0379 (1). This small-molecule inhibitor is active in multiple biochemical assays. Its affinity to SETD8 was confirmed by ITC (isothermal titration calorimetry) and SPR (surface plasmon resonance) studies. Importantly, compound 1 is selective for SETD8 over 15 other methyltransferases. We also describe structure-activity relationships (SAR) of this series.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据